Dermatomyositis: An Acute Flare and Current Treatments

The purpose of this case report is to assess and review the literature to determine the frequency of occurrence of dermatomyositis (DM). Dermatomyositis is a rare autoimmune condition that disproportionately affects adolescence and pediatric patients. The symptomatology experienced in this condition includes but not limited to fatigue, reduced mobility, and dysphagia. Symptoms of dysphonia and dyspnea have been reported due to weakened esophageal and respiratory muscle. Another major complication seen in DM is calcinosis. Calcinosis is a calcium deposit on soft tissue. This is mostly been attributed to late diagnosis or use of ineffective treatment regimen. Systemic corticosteroid is the first-line treatment for DM; however, other agents such as anti-malaria, IVIG, and immunosuppressive therapies have been used successfully.

Download Full-text

OK-432 treatment of pediatric patients with recurrent thyroglossal duct cyst after surgery

Otolaryngologia Polska ◽

10.5604/01.3001.0014.9073 ◽

2021 ◽

Vol 75 (4) ◽

pp. 1-4

Author(s):

Nobuo Ohta ◽

Shigeru Fukase ◽

Miho Nakazumi ◽

Teruyuki Sato ◽

Takahiro Suzuki

Keyword(s):

Pediatric Patients ◽

Case Series ◽

Rare Condition ◽

Thyroglossal Duct Cyst ◽

Outpatient Basis ◽

First Line ◽

Duct Cyst ◽

Thyroglossal Duct ◽

Total Shrinkage ◽

First Line Treatment

Introduction: Recurrent thyroglossal duct cyst after surgery is not a rare condition and first-line treatment has not been established yet. Aim: Evaluation of outcomes and complications of OK-432 treatment in patients with recurrent thyroglossal duct cyst after surgery. Material and methods: This study is designed as a case series with planned data collection at Tohoku Medical and Pharmaceutical University and Fukase Clinic. Five patients with recurrent thyroglossal duct cyst after surgery received this therapy between January 2014 and February 2020 on an outpatient basis, without hospitalization. OK-432 solution was injected into the lesion using an 18- or 27-gauge needle, depending on the location and size of the lesion, as well as on possible complications. Results: Lesions showed marked reduction or total shrinkage in all patients, with no local scarring or deformity at the injection site. Side effects manifested as local pain at the site of injection and fever (37.5–38.5°C) observed in three patients, but the symptoms resolved within a few days. Conclusions: Since OK-432 therapy is simple, easy, safe and effective, it can be used as an alternative to surgery in the treatment of recurrent thyroglossal duct cyst after surgery.

Download Full-text

Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls

The Journal of Pediatric Pharmacology and Therapeutics ◽

10.5863/1551-6776-25.7.586 ◽

2020 ◽

Vol 25 (7) ◽

pp. 586-599

Author(s):

Laura Tiemann ◽

Sarrah Hein

Keyword(s):

Health Care Providers ◽

Pediatric Patients ◽

Medication Management ◽

Infantile Hemangioma ◽

Vascular Tumor ◽

Small Subset ◽

Care Providers ◽

First Line ◽

Life Threatening ◽

First Line Treatment

Infantile hemangioma (IH) is the most common vascular tumor of infancy, affecting as many as 5% to 10% of all infants. The exact cause is unclear, but specific risk factors, such as low birth weight, prematurity, female sex, white race, and family history are associated with IH development. Most IHs are benign and self-resolving, but a small subset of patients with IHs are at risk of severe or life-threatening outcomes. Systemic and topical β-blockers are effective and safe for use in pediatric patients and considered first-line treatment for both complicated and uncomplicated IHs. Recently published guidelines provide a thorough review of IH and management. This article focuses on IH pharmacotherapy and provides practice pearls to support health care providers in IH medication management.

Download Full-text

Longitudinal Growth Outcomes Following First-line Treatment for Pediatric Patients With Eosinophilic Esophagitis

Journal of Pediatric Gastroenterology and Nutrition ◽

10.1097/mpg.0000000000002114 ◽

2019 ◽

Vol 68 (1) ◽

pp. 50-55 ◽

Cited By ~ 8

Author(s):

Elizabeth T. Jensen ◽

Kevin Z. Huang ◽

Hannah X. Chen ◽

Lisa E. Landes ◽

Kristen A. McConnell ◽

...

Keyword(s):

Eosinophilic Esophagitis ◽

Pediatric Patients ◽

Longitudinal Growth ◽

Line Treatment ◽

First Line ◽

Growth Outcomes ◽

First Line Treatment

Download Full-text

Pemphigus Vulgaris Combination Adjuvant Therapy of Systemic Corticosteroid with Sparing Agent Sodium Mycophenolate

Archives of The Medicine and Case Reports ◽

10.37275/amcr.v1i1.1 ◽

2020 ◽

Vol 1 (1) ◽

pp. 1-10

Author(s):

Nopriyati Nopriyati ◽

Cayadi Sidarta Antonius ◽

Susanti Budiamal ◽

Inda Astri Aryani

Keyword(s):

Side Effects ◽

Autoimmune Disease ◽

Systemic Corticosteroid ◽

Pemphigus Vulgaris ◽

Direct Immunofluorescence ◽

Histopathologic Examination ◽

Line Treatment ◽

First Line ◽

Posterior Trunk ◽

First Line Treatment

Pemphigus Vulgaris (PV) is an autoimmune disease characterized by vesicles and bullae onthe skin and mucosa resulting from an autoantibody reaction to desmosomal adhesion moleculesdesmoglein (Dsg) 1 and 3, which function as strong adhesions between keratinocytes. PemphigusVulgaris is more common in the fifth and sixth decades of age. The lesions are fragile blisters on themucosa and skin. Diagnosing PV requires anamnesis, physical examination, and investigations suchas histopathologic examination and direct immunofluorescence. Therapy generally uses steroids.Adjuvant treatment is given to reduce the side effects of corticosteroids. We reported a male, 59 yearsold, was treated with blisters that break easily into blisters on the head, face, chest, back, groin andbuttocks accompanied by burning and itching. In the scalp, facial, anterior et posterior trunk, inguinal,and gluteal regions, multiple erythematous macules were found with lenticular-plaque shape; it waspartially confluent with thick brown crusts which were challenging to remove. The histopathologicexamination found the presence of suprabasal bullae with lymphocyte inflammation cells. The patientwas diagnosed with PV and treated with corticosteroids with the sparing agent mycophenolate sodiumand showed clinical improvement. The first-line treatment for pemphigus Vulgaris is systemiccorticosteroids. Adjuvant sparing agent therapy is given to reduce the side effects of corticosteroids.Sodium mycophenolate sparing agent was selected because of its minimum side effects. In systemicmanagement, the dose of corticosteroid and sparing agent mycophenolate sodium was graduallydecreased. The patient experienced initial remission after treatment

Download Full-text